Top stories in endocrinology: Beta-cell function normalizes in type 2 diabetes remission, once-daily pill lowers HbA1c in type 1 diabetes
Click Here to Manage Email Alerts
Adults with type 2 diabetes who lost enough weight to enter diabetes remission were also able to achieve normal beta-cell function. It was the top story in endocrinology last week.
Another top story showed that adding an investigational, once-daily pill to optimized insulin therapy reduced HbA1c among adults with type 1 diabetes.
Read these and more popular stories in endocrinology below:
Weight-loss that remits type 2 diabetes normalizes beta-cell function
Adults with type 2 diabetes who lose enough weight to enter diabetes remission are also able to recapture normal beta-cell capacity, according to findings published in Diabetes Care. Read more.
Novel once-daily pill reduces HbA1c in type 1 diabetes
An investigational, once-daily pill added to optimized insulin therapy was shown to reduce HbA1c among adults with type 1 diabetes during a 12-week trial when compared with placebo plus insulin, according to a press release from vTv Therapeutics. Read more.
Regular thyroid testing recommended regardless of diabetes type
Thyroid dysfunction is common among people with diabetes regardless of type, suggesting that biochemical thyroid screening should be a part of routine management for those with type 1 and type 2, according to an analysis of a community-based study published in Clinical Endocrinology. Read more.
Discontinuing antidepressants, lowering dose alleviates treatment-induced type 2 diabetes
Japanese adults may be at greater risk for type 2 diabetes if they take antidepressants, but high HbA1c can be addressed by taking a lower dose or discontinuing the drugs, according to findings published in Diabetes Care. Read more.
New drug combination induces human beta-cell regeneration at unprecedented rates
GLP-1 receptor agonists, widely used to treat type 2 diabetes, can be converted into “potent beta-cell regenerative drugs” when combined with any member of the DYRK1A inhibitor class, according to study findings published in Science Translational Medicine, and researchers have demonstrated the treatment may have promise beyond in vitro models. Read more.